AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS SAN DIEGO, May 1 /PRNewswire/ -- Agouron Pharmaceuticals Inc.
(NASDAQ/NMS: AGPH) today announced a net loss for the third quarter and nine months ended March 31, 1992, of $1,848,000, or $.27 per common share, and $6,435,000, or $1.08 per share, respectively. The net loss recorded in each comparable period of the prior fiscal year was $1,669,000, or $.35 per share, and $4,869,000, or $1.06 per share.
Agouron Pharmaceuticals Inc. is a pioneer and leader in a new technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases. AGOURON PHARMACEUTICALS INC. Summary Financial Information (Dollars in thousands except per share amounts) Three months ended Nine months ended March 31, March 31, 1992 1991 1992 1991 Revenues $2,161 $1,146 $4,734 $3,592 Net loss ($1,848) ($1,669) ($6,435) ($4,869) Net loss per common share ($.27) ($.35) ($1.08) ($1.06) Shares used in computing net loss per common share 6,865,000 4,837,000 5,965,000 4,608,000 -0- 5/1/92 /CONTACT: Steven S. Cowell, vice president and CFO, or Donna Nichols, manager of corporate communications of Agouron Pharmaceuticals, 619-622-3000/ (AGPH) CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: ERN
CH-MC -- SD002 -- 5635 05/01/92 17:03 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||May 1, 1992|
|Previous Article:||WASHINGTON STATE REPUBLICAN CHAIRMAN SAYS DEMOCRATS SHOULD HOLD HEADS IN SHAME FOR RESISTING SUBPOENA OF HOUSE BANK RECORDS|
|Next Article:||NEW DEALER FACILITY PART OF BUICK DESIGN PROGRAM|